CN112533916A - 一种作用于crbn蛋白的三并环类化合物 - Google Patents

一种作用于crbn蛋白的三并环类化合物 Download PDF

Info

Publication number
CN112533916A
CN112533916A CN201980052516.1A CN201980052516A CN112533916A CN 112533916 A CN112533916 A CN 112533916A CN 201980052516 A CN201980052516 A CN 201980052516A CN 112533916 A CN112533916 A CN 112533916A
Authority
CN
China
Prior art keywords
alkyl
radical
reaction mixture
reaction
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980052516.1A
Other languages
English (en)
Other versions
CN112533916B (zh
Inventor
雷茂义
罗云富
徐雨
张国利
于志娟
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202210606710.3A priority Critical patent/CN115109074A/zh
Publication of CN112533916A publication Critical patent/CN112533916A/zh
Application granted granted Critical
Publication of CN112533916B publication Critical patent/CN112533916B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

公开了一系列三并环类化合物，及其在制备治疗与CRBN蛋白相关疾病药物中的应用，具体公开了式(I)所示衍生化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (23)

  1. PCT国内申请，权利要求书已公开。
CN201980052516.1A 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物 Active CN112533916B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210606710.3A CN115109074A (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2018110459411 2018-09-07
CN201811045941 2018-09-07
CN2018113549867 2018-11-14
CN201811354986 2018-11-14
CN2019102225977 2019-03-22
CN201910222597 2019-03-22
PCT/CN2019/104996 WO2020048548A1 (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210606710.3A Division CN115109074A (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物

Publications (2)

Publication Number Publication Date
CN112533916A true CN112533916A (zh) 2021-03-19
CN112533916B CN112533916B (zh) 2022-05-20

Family

ID=69721960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210606710.3A Pending CN115109074A (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物
CN201980052516.1A Active CN112533916B (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210606710.3A Pending CN115109074A (zh) 2018-09-07 2019-09-09 一种作用于crbn蛋白的三并环类化合物

Country Status (11)

Country Link
US (1) US20220119376A1 (zh)
EP (1) EP3848367A4 (zh)
JP (1) JP7422139B2 (zh)
KR (1) KR20210057767A (zh)
CN (2) CN115109074A (zh)
AU (1) AU2019334065A1 (zh)
BR (1) BR112021004269A2 (zh)
CA (1) CA3111649A1 (zh)
IL (1) IL281296B1 (zh)
SG (1) SG11202102271WA (zh)
WO (1) WO2020048548A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3848371A4 (en) * 2018-09-07 2022-06-08 Medshine Discovery Inc. TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND
EP3848363B1 (en) * 2018-09-07 2023-07-19 Medshine Discovery Inc. Tricyclic substituted piperidine dione compound
US11905276B2 (en) * 2019-09-12 2024-02-20 Medshine Discovery Inc. Bicyclic compound that acts as CRBN protein regulator
WO2021175317A1 (zh) * 2020-03-06 2021-09-10 正大天晴药业集团股份有限公司 一种作用于crbn蛋白的三并环类化合物的结晶及其制备方法
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc PROTEOLYSIS REGULATOR AND METHOD OF USE
CN117580575A (zh) * 2021-06-17 2024-02-20 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
CN117751112A (zh) * 2021-07-19 2024-03-22 南京明德新药研发有限公司 杂芳-3-哌啶二酮类化合物及其应用
TW202321263A (zh) * 2021-08-10 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 磺醯胺衍生物、其製備方法及其在醫藥上的應用
TW202325300A (zh) * 2021-11-18 2023-07-01 大陸商正大天晴藥業集團股份有限公司 稠合醯亞胺類衍生物及其應用
WO2024037616A1 (zh) * 2022-08-19 2024-02-22 正大天晴药业集团股份有限公司 包含环己基的化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101223168A (zh) * 2005-07-14 2008-07-16 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CN101772501A (zh) * 2007-06-18 2010-07-07 先灵公司 杂环化合物及其作为erk抑制剂的用途
WO2017152076A1 (en) * 2016-03-04 2017-09-08 Vanderbilt University Substituted indole mcl-1 inhibitors
CN107548397A (zh) * 2015-03-13 2018-01-05 4Sc股份公司 Kv1.3抑制剂及其医学应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080026654A (ko) 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
EP3848371A4 (en) 2018-09-07 2022-06-08 Medshine Discovery Inc. TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND
EP3848363B1 (en) 2018-09-07 2023-07-19 Medshine Discovery Inc. Tricyclic substituted piperidine dione compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101223168A (zh) * 2005-07-14 2008-07-16 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
CN101772501A (zh) * 2007-06-18 2010-07-07 先灵公司 杂环化合物及其作为erk抑制剂的用途
CN107548397A (zh) * 2015-03-13 2018-01-05 4Sc股份公司 Kv1.3抑制剂及其医学应用
WO2017152076A1 (en) * 2016-03-04 2017-09-08 Vanderbilt University Substituted indole mcl-1 inhibitors

Also Published As

Publication number Publication date
WO2020048548A1 (zh) 2020-03-12
SG11202102271WA (en) 2021-04-29
AU2019334065A1 (en) 2021-04-15
KR20210057767A (ko) 2021-05-21
IL281296B1 (en) 2024-04-01
JP2021536480A (ja) 2021-12-27
CN115109074A (zh) 2022-09-27
JP7422139B2 (ja) 2024-01-25
EP3848367A1 (en) 2021-07-14
BR112021004269A2 (pt) 2021-05-25
US20220119376A1 (en) 2022-04-21
EP3848367A4 (en) 2022-06-08
CN112533916B (zh) 2022-05-20
IL281296A (en) 2021-04-29
CA3111649A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
CN112533916B (zh) 一种作用于crbn蛋白的三并环类化合物
CN112654619B (zh) 三环并呋喃取代哌啶二酮类化合物
CN112689627B (zh) 三环取代哌啶二酮类化合物
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
CN111247151B (zh) 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用
CN115702156A (zh) 吡啶酰胺类化合物
CN114456159A (zh) 氮取代杂环噻吩类化合物及其用途
CN115380026A (zh) 蛋白降解调节剂与其使用方法
CN114456147A (zh) 氧取代氨基碳酸酯噻吩类化合物
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
CN110621670A (zh) 作为布鲁顿氏酪氨酸激酶的抑制剂的苯并氮杂卓类似物
CN112771045B (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
CN106892948A (zh) 吡喃葡萄糖基衍生物及其在医药上的应用
CN111344282A (zh) 喹唑啉酮类化合物及其应用
CN115772180A (zh) 戊二酰亚胺类化合物与其应用
KR20230154953A (ko) 푸란 축합 고리로 치환된 글루타르이미드계 화합물
CN103508931A (zh) 六氢并环戊二烯衍生物、其制备方法及其在医药上的应用
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
WO2023208127A1 (zh) 杂芳基取代的双环化合物及其应用
CN112574278A (zh) 作为蛋白降解剂杂环类化合物及其制备方法和医药应用
WO2023109878A1 (zh) 三氮唑类lpar1拮抗剂及其用途
CN114437038A (zh) 哒嗪炔烃类化合物及其用途
CN115515963A (zh) 嘧啶三并环类化合物及其应用
CN111356692B (zh) Ido抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210623

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042857

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant